Table 3.
Results of ATN classification using CSF biomarkers
| Interpretation | Biomarker profile | Amnestic Alzheimer’s disease (n = 98) | Non-amnestic Alzheimer’s disease (n = 20) | Amnestic FTLD (n = 5) | Non-amnestic FTLD (n = 59) |
|---|---|---|---|---|---|
| Alzheimer's continuum | |||||
| Alzheimer’s disease | A+T+N+ | 51 (52%) | 4 (20%) | 0 (0%) | 0 (0%) |
| A+T+N− | 16 (16%) | 5 (25%) | 0 (0%) | 0 (0%) | |
| Alzheimer’s pathological change | A+T−N− | 13 (13%) | 6 (30%) | 2 (40%) | 7 (12%) |
| Alzheimer’s disease and concomitant suspected non-Alzheimer’s disease pathological change | A+T−N+ | 11 (11%) | 2 (10%) | 1 (20%) | 2 (3%) |
| Non-Alzheimer’s pathological change | A−T+N− | 2 (2%) | 0 (0%) | 0 (0%) | 2 (3%) |
| A−T−N+ | 0 (0%) | 0 (0%) | 0 (0%) | 7 (12%) | |
| A−T+N+ | 3 (3%) | 0 (0%) | 0 (0%) | 3 (5%) | |
| Normal biomarkers | A−T−N− | 2 (2%) | 3 (15%) | 2 (40%) | 38 (64%) |
| Alzheimer’s disease | p-tau/Aβ1–42 ≥ 0.1 | 88 (90%) | 13 (65%) | 1 (20%) | 9 (15%) |
Interpretation of biomarkers using ATN framework and p-tau/Aβ1–42 ratio (bottom row).